ATOMIC Meso Trial - Revision history

MesotheliomaSupport: fix(render): replace {{clear|right}} template (Template:Clear undefined on this wiki = redlink) with raw HTML div for float-clear

2026-05-28T15:30:33Z

fix(render): replace {{clear|right}} template (Template:Clear undefined on this wiki = redlink) with raw HTML div for float-clear

← Older revision		Revision as of 15:30, 28 May 2026
Line 62:		Line 62:
	As of May 2026, pegargiminase has not yet received U.S. Food and Drug Administration (FDA) approval specifically for mesothelioma. Regulatory discussions with the sponsor, Polaris Pharmaceuticals, are ongoing. Access is currently limited to expanded-access programs and select academic centers.		As of May 2026, pegargiminase has not yet received U.S. Food and Drug Administration (FDA) approval specifically for mesothelioma. Regulatory discussions with the sponsor, Polaris Pharmaceuticals, are ongoing. Access is currently limited to expanded-access programs and select academic centers.

	{{clear\|right}}		<div style="clear:right;"></div>

	== At a Glance ==		== At a Glance ==

MesotheliomaSupport: At a Glance: convert wikitable to 8-bullet listicle per A++ template + CLEO #10257 + pre-flight v4 (Fix 2; Fix 1 {{clear|right}} already shipped b8ddc35)

2026-05-28T15:26:53Z

At a Glance: convert wikitable to 8-bullet listicle per A++ template + CLEO #10257 + pre-flight v4 (Fix 2; Fix 1 {{clear|right}} already shipped b8ddc35)

@@ Line 66: / Line 66: @@
 == At a Glance ==
-{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
+* ATOMIC-Meso (NCT02709512) — Phase 2-3 double-blind randomized placebo-controlled trial in chemotherapy-naive nonepithelioid pleural mesothelioma
-|-
+* Enrolled 249 patients across 43 centers in 5 countries, randomized 1:1 to pegargiminase + pemetrexed/platinum or placebo + chemotherapy
-! style="background:#1a5276; color:white; padding:10px; text-align:left; width:35%;" | Item
+* Met primary endpoint of overall survival: median 9.3 months on pegargiminase vs 7.7 months on placebo (hazard ratio 0.71, 95% CI 0.55–0.93, P=.02)
-! style="background:#1a5276; color:white; padding:10px; text-align:left;" | Detail
+* Secondary endpoint progression-free survival also met: median 6.2 vs 5.6 months (hazard ratio 0.65, 95% CI 0.46–0.90, P=.02)
-|-
+* Pegargiminase (ADI-PEG20) is a pegylated bacterial enzyme that depletes circulating arginine, exploiting ASS1 deficiency in nonepithelioid tumors
-| style="padding:10px; font-weight:bold;" | Trial Name
+* First Phase 3 trial restricted to first-line nonepithelioid pleural mesothelioma — sarcomatoid and biphasic — to meet a positive primary survival endpoint
-| style="padding:10px;" | ATOMIC-Meso (NCT02709512)
+* Published in ''JAMA Oncology'', April 2024, lead investigator Peter W. Szlosarek, MD (Barts Cancer Institute), sponsor Polaris Group
-|-
+* Not yet FDA-approved as of May 2026; access through expanded-access programs and select academic centers
 == Key Facts ==

MesotheliomaSupport: fix(render): insert {{clear|right}} between Executive Summary and At a Glance to clear infobox float-eclipse on wider viewports (CLEO #10255)

2026-05-28T15:23:09Z

fix(render): insert {{clear|right}} between Executive Summary and At a Glance to clear infobox float-eclipse on wider viewports (CLEO #10255)

← Older revision		Revision as of 15:23, 28 May 2026
Line 61:		Line 61:

	As of May 2026, pegargiminase has not yet received U.S. Food and Drug Administration (FDA) approval specifically for mesothelioma. Regulatory discussions with the sponsor, Polaris Pharmaceuticals, are ongoing. Access is currently limited to expanded-access programs and select academic centers.		As of May 2026, pegargiminase has not yet received U.S. Food and Drug Administration (FDA) approval specifically for mesothelioma. Regulatory discussions with the sponsor, Polaris Pharmaceuticals, are ongoing. Access is currently limited to expanded-access programs and select academic centers.

			{{clear\|right}}

	== At a Glance ==		== At a Glance ==

MesotheliomaSupport: Create ATOMIC-Meso Trial canonical wiki — Phase 2-3 pegargiminase + chemotherapy in nonepithelioid pleural mesothelioma (PMID 38358753 Szlosarek 2024 JAMA Oncol). CLEO #10143 cycle 2 APPROVED; #10148 slug-as-literal repost satisfies cleo-pass-gate.

2026-05-28T13:53:36Z

Create ATOMIC-Meso Trial canonical wiki — Phase 2-3 pegargiminase + chemotherapy in nonepithelioid pleural mesothelioma (PMID 38358753 Szlosarek 2024 JAMA Oncol). CLEO #10143 cycle 2 APPROVED; #10148 slug-as-literal repost satisfies cleo-pass-gate.

New page

{{#seo:
|title=ATOMIC-Meso Trial: First-Line Pegargiminase for Nonepithelioid Mesothelioma
|title_mode=replace
|description=ATOMIC-Meso (JAMA Oncology 2024): pegargiminase + chemotherapy extended median overall survival to 9.3 vs 7.7 months (HR 0.71) in nonepithelioid pleural mesothelioma.
|keywords=ATOMIC-Meso, pegargiminase, ADI-PEG20, nonepithelioid mesothelioma, sarcomatoid mesothelioma, biphasic mesothelioma, arginine deprivation, ASS1 deficiency, Phase 3 trial, Szlosarek, JAMA Oncology, mesothelioma clinical trial
|image=atomic-meso-trial-results.jpg
|image_alt=WikiMesothelioma — ATOMIC-Meso Trial
|author=Danziger & De Llano Legal Team
|published_time=2026-05-28
|type=Article
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; background:#ffffff; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | ATOMIC-Meso Trial
|-
| colspan="2" style="background:#e8f4f8; padding:10px; text-align:center; font-style:italic;" | Pegargiminase Phase 2-3 in Nonepithelioid Mesothelioma
|-
| style="padding:10px; font-weight:bold; width:45%; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Registry ID
| style="padding:10px; border-bottom:1px solid #dee2e6;" | NCT02709512
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Trial Type
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Phase 2-3, double-blind, randomized, placebo-controlled
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Sites / Countries
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 43 centers across 5 countries
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Population
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Nonepithelioid pleural mesothelioma (sarcomatoid + biphasic), chemotherapy-naive
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Patients Enrolled
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 249
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Primary Endpoint
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Overall survival (OS)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Median OS (Primary)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 9.3 vs 7.7 months (HR 0.71, P=.02)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Median PFS (Secondary)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | 6.2 vs 5.6 months (HR 0.65, P=.02)
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Lead Investigator
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Peter W. Szlosarek, MD
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa; border-bottom:1px solid #dee2e6;" | Sponsor
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Polaris Pharmaceuticals
|-
| style="padding:10px; font-weight:bold; background:#f8f9fa;" | Primary Publication
| style="padding:10px;" | ''JAMA Oncology'', April 2024
|}

== Executive Summary ==

The '''ATOMIC-Meso Trial''' is a Phase 2-3 double-blind, randomized, placebo-controlled study that tested whether adding pegargiminase — a pegylated bacterial enzyme that depletes circulating arginine — to first-line chemotherapy improves survival in patients with nonepithelioid (sarcomatoid and biphasic) malignant pleural mesothelioma (MPM). The trial enrolled 249 chemotherapy-naive patients at 43 centers across 5 countries from August 2017 through August 2021, randomized them 1:1 to pegargiminase + pemetrexed/platinum or placebo + pemetrexed/platinum, and reported results in ''JAMA Oncology'' in April 2024.<ref name="pmid:38358753">Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, et al. [https://pubmed.ncbi.nlm.nih.gov/38358753/ Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.] ''JAMA Oncology''. 2024;10(4):475-483. doi:10.1001/jamaoncol.2023.6789. PMID: 38358753.</ref>

The trial met its primary endpoint of overall survival (OS). Median overall survival was 9.3 months in the pegargiminase arm versus 7.7 months in the placebo arm — a hazard ratio for death of 0.71 (95% confidence interval [CI] 0.55–0.93; P = .02). Median progression-free survival, a secondary endpoint, was also significantly extended: 6.2 versus 5.6 months, hazard ratio 0.65 (95% CI 0.46–0.90; P = .02), representing a 35% reduction in the risk of disease progression or death.<ref name="pmid:38358753"/>

ATOMIC-Meso is the first positive Phase 3 result of an arginine-deprivation strategy in any solid tumor and the most significant treatment advance specifically for nonepithelioid mesothelioma in approximately two decades. Nonepithelioid disease — particularly the sarcomatoid subtype — has historically been excluded from or underrepresented in immunotherapy trials and has consistently shown worse outcomes than epithelioid mesothelioma across every standard of care.

The trial exploits a metabolic vulnerability: many mesothelioma tumors silence the enzyme '''argininosuccinate synthetase 1''' (ASS1) through epigenetic methylation, leaving the cancer cell unable to synthesize its own arginine. Pegargiminase systemically degrades extracellular arginine, starving ASS1-deficient tumor cells of a building block they cannot replace. The mechanism is most active in nonepithelioid subtypes, where ASS1 deficiency rates approach 90%.<ref name="pmid:27584578">Szlosarek PW, Steele JP, Nolan L, Gilligan D, Taylor P, Spicer J, Lind M, Mitra S, et al. [https://pubmed.ncbi.nlm.nih.gov/27584578/ Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.] ''JAMA Oncology''. 2017;3(1):58-66. doi:10.1001/jamaoncol.2016.3049. PMID: 27584578.</ref>

As of May 2026, pegargiminase has not yet received U.S. Food and Drug Administration (FDA) approval specifically for mesothelioma. Regulatory discussions with the sponsor, Polaris Pharmaceuticals, are ongoing. Access is currently limited to expanded-access programs and select academic centers.

== At a Glance ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px; text-align:left; width:35%;" | Item
! style="background:#1a5276; color:white; padding:10px; text-align:left;" | Detail
|-
| style="padding:10px; font-weight:bold;" | Trial Name
| style="padding:10px;" | ATOMIC-Meso (NCT02709512)
|-
| style="padding:10px; font-weight:bold;" | Disease
| style="padding:10px;" | Chemotherapy-naive nonepithelioid (sarcomatoid + biphasic) malignant pleural mesothelioma (MPM)
|-
| style="padding:10px; font-weight:bold;" | Trial Design
| style="padding:10px;" | Phase 2-3, double-blind, randomized 1:1, placebo-controlled
|-
| style="padding:10px; font-weight:bold;" | Treatment Tested
| style="padding:10px;" | Pegargiminase (ADI-PEG20) 36.8 mg/m² intramuscular (IM) weekly + pemetrexed/platinum vs placebo + pemetrexed/platinum
|-
| style="padding:10px; font-weight:bold;" | Sites
| style="padding:10px;" | 43 centers across 5 countries
|-
| style="padding:10px; font-weight:bold;" | Patients Enrolled
| style="padding:10px;" | 249, randomized 1:1
|-
| style="padding:10px; font-weight:bold;" | Primary Endpoint
| style="padding:10px;" | Overall survival (OS)
|-
| style="padding:10px; font-weight:bold;" | Median Overall Survival (Primary)
| style="padding:10px;" | 9.3 months (pegargiminase) vs 7.7 months (placebo); hazard ratio (HR) 0.71 (95% confidence interval [CI] 0.55–0.93; P=.02)
|-
| style="padding:10px; font-weight:bold;" | Median Progression-Free Survival (Secondary)
| style="padding:10px;" | 6.2 months vs 5.6 months; HR 0.65 (95% CI 0.46–0.90; P=.02)
|-
| style="padding:10px; font-weight:bold;" | Mechanism
| style="padding:10px;" | Systemic arginine depletion exploits ASS1 (argininosuccinate synthetase 1) deficiency in nonepithelioid tumors
|-
| style="padding:10px; font-weight:bold;" | Lead Investigator
| style="padding:10px;" | Peter W. Szlosarek, MD (Barts Cancer Institute, Queen Mary University of London)
|-
| style="padding:10px; font-weight:bold;" | Sponsor
| style="padding:10px;" | Polaris Pharmaceuticals (now Polaris Group)
|-
| style="padding:10px; font-weight:bold;" | Primary Publication
| style="padding:10px;" | ''JAMA Oncology'', April 2024
|-
| style="padding:10px; font-weight:bold;" | Regulatory Status
| style="padding:10px;" | No FDA-approved indication as of May 2026; expanded access at select centers
|}

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#0d6efd; color:white; padding:10px; text-align:left;" | Fact
! style="background:#0d6efd; color:white; padding:10px; text-align:left;" | Source
|-
| style="padding:10px;" | ATOMIC-Meso enrolled 249 chemotherapy-naive patients with nonepithelioid pleural mesothelioma at 43 centers across 5 countries between August 2017 and August 2021; randomization was 1:1 to pegargiminase + chemotherapy or placebo + chemotherapy.
| style="padding:10px;" | Szlosarek et al., ''JAMA Oncology'' 2024<ref name="pmid:38358753"/>
|-
| style="padding:10px;" | The primary endpoint was overall survival. Median overall survival was 9.3 months for pegargiminase + chemotherapy versus 7.7 months for placebo + chemotherapy; hazard ratio for death 0.71 (95% confidence interval 0.55–0.93; P=.02).
| style="padding:10px;" | Szlosarek et al., ''JAMA Oncology'' 2024<ref name="pmid:38358753"/>
|-
| style="padding:10px;" | Secondary endpoint median progression-free survival was 6.2 months versus 5.6 months; hazard ratio 0.65 (95% CI 0.46–0.90; P=.02), representing a 35% reduction in the risk of progression or death.
| style="padding:10px;" | Szlosarek et al., ''JAMA Oncology'' 2024<ref name="pmid:38358753"/>
|-
| style="padding:10px;" | The trial mechanism depends on tumor-cell ASS1 deficiency, which is present in roughly 90% of nonepithelioid pleural mesothelioma and approximately half of epithelioid tumors.
| style="padding:10px;" | Szlosarek et al., ''JAMA Oncology'' 2017 (ADAM trial)<ref name="pmid:27584578"/>
|-
| style="padding:10px;" | Pegargiminase development began with a Phase 1 dose-escalation study published in ''Journal of Clinical Oncology'' in 2017 and an expansion Phase 1 study published in ''JTO Clinical and Research Reports'' in 2020.
| style="padding:10px;" | Beddowes et al., ''JCO'' 2017<ref name="pmid:28388291">Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW. [https://pubmed.ncbi.nlm.nih.gov/28388291/ Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers.] ''Journal of Clinical Oncology''. 2017;35(16):1778-1785. doi:10.1200/JCO.2016.71.3230. PMID: 28388291.</ref>; Szlosarek et al., ''JTO Clin Res Rep'' 2020<ref name="pmid:34589965">Szlosarek PW, Phillips MM, Pavlyk I, Steele J, Shamash J, Spicer J, Kumar S, Pacey S, Feng X, Johnston A, Bomalaski J, Moir G, Lau K, Ellis S, Sheaff M. [https://pubmed.ncbi.nlm.nih.gov/34589965/ Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1-Deficient Mesothelioma.] ''JTO Clinical and Research Reports''. 2020;1(4):100093. doi:10.1016/j.jtocrr.2020.100093. PMID: 34589965.</ref>
|-
| style="padding:10px;" | The most common Grade 3 or higher adverse events were anemia and neutropenia, in line with platinum/pemetrexed toxicity; immunogenicity (anti-drug antibodies) developed in roughly two-thirds of patients but did not abolish clinical benefit.
| style="padding:10px;" | Szlosarek et al., ''JAMA Oncology'' 2024<ref name="pmid:38358753"/>
|-
| style="padding:10px;" | The companion biomarker hypothesis — that '''[[BAP1]] loss alters ASS1 expression in epithelioid mesothelioma''' and therefore changes which patients benefit from arginine deprivation — was published in ''Molecular Cancer Research'' in 2023.
| style="padding:10px;" | Barnett et al., ''Mol Cancer Res'' 2023<ref name="pmid:36669126">Barnett SE, Kenyani J, Tripari M, Butt Z, Grosman R, Querques F, Shaw L, Silva LC, Goate Z, Marciniak SJ, Rassl DM, Jackson R, Lian LY, Szlosarek PW, Sacco JJ, Coulson JM. [https://pubmed.ncbi.nlm.nih.gov/36669126/ BAP1 Loss Is Associated with Higher ASS1 Expression in Epithelioid Mesothelioma: Implications for Therapeutic Stratification.] ''Molecular Cancer Research''. 2023;21(5):411-427. doi:10.1158/1541-7786.MCR-22-0635. PMID: 36669126.</ref>
|}

== Why Was ATOMIC-Meso Needed? ==

Malignant pleural mesothelioma is divided into three histologic subtypes based on tumor cell morphology: epithelioid (~60% of cases), biphasic (~20%), and sarcomatoid (~15%). The remainder are unclassified or rare variants. Across every line of therapy and every era of treatment, '''nonepithelioid disease — sarcomatoid more so than biphasic — has been associated with substantially worse outcomes than epithelioid mesothelioma'''.

The two most consequential therapeutic advances of the last decade — first-line dual immunotherapy with nivolumab plus ipilimumab approved in 2020 based on the [[CheckMate_743_Trial|CheckMate 743 trial]], and second-line bevacizumab + atezolizumab combinations — extended overall survival across mesothelioma broadly. But they did so primarily through gains in the epithelioid subgroup. The non-epithelioid subgroup of [[CheckMate_743_Trial|CheckMate 743]] showed a substantial benefit from immunotherapy compared with chemotherapy alone, but the absolute survival numbers remained low: median survival in the 12-month range, with single-digit 5-year survival rates.

For patients with sarcomatoid or biphasic mesothelioma, the standard-of-care toolkit before ATOMIC-Meso reported was effectively (1) pemetrexed plus a platinum agent — a chemotherapy regimen unchanged in its basic shape since 2003 — or (2) dual immunotherapy, with response rates and median survival measured in months rather than years. A new mechanism specifically suited to nonepithelioid biology had been missing from the field for two decades.

ATOMIC-Meso was designed to fill that gap by exploiting the metabolic vulnerability that nonepithelioid mesotheliomas tend to share: '''ASS1 deficiency'''.

== The Biology: Arginine Deprivation and ASS1 ==

Arginine is a conditionally essential amino acid required for cancer cell growth, protein synthesis, polyamine production, and survival. Normal human cells can synthesize arginine intracellularly through the urea cycle, in which argininosuccinate synthetase 1 (ASS1) catalyzes a key step. Most healthy tissues maintain functional ASS1 expression and can compensate when extracellular arginine is depleted.

Many cancers, however — including a large fraction of mesotheliomas — '''epigenetically silence ASS1 expression''' through promoter hypermethylation. The result is a tumor cell that cannot synthesize arginine internally and depends on circulating, extracellular arginine for survival. This dependency is sometimes called "arginine auxotrophy."<ref name="pmid:27584578"/>

ASS1 deficiency rates in malignant pleural mesothelioma vary by subtype:

* Nonepithelioid (sarcomatoid and biphasic): approximately 90% ASS1-deficient
* Epithelioid: approximately 50–60% ASS1-deficient

This subtype-level difference is the rationale for restricting the ATOMIC-Meso Phase 3 enrollment to nonepithelioid disease. The same biology that makes sarcomatoid tumors so difficult to treat with conventional chemotherapy and immunotherapy — their stromal-rich, mesenchymal phenotype — is the biology that makes them most vulnerable to arginine deprivation.

=== How Pegargiminase Works ===

Pegargiminase (also known as ADI-PEG20, sometimes spelled ADI-PEG 20) is a '''pegylated form of arginine deiminase''', a bacterial enzyme originally derived from ''Mycoplasma''. Arginine deiminase converts circulating L-arginine to citrulline plus ammonia. The pegylation — covalent attachment of polyethylene glycol (PEG) chains — extends the enzyme's half-life in human circulation from minutes to days, making weekly dosing feasible. Pegylation also reduces immunogenicity, though it does not eliminate it.

Once injected intramuscularly, pegargiminase depletes plasma arginine to undetectable levels within 24 to 48 hours, and arginine remains suppressed throughout the dosing interval. Normal cells survive because they can upregulate ASS1 and produce their own arginine from citrulline. ASS1-deficient tumor cells, however, cannot make this metabolic switch and are progressively starved of a building block essential to protein synthesis and survival.<ref name="pmid:27584578"/>

The kinetics matter clinically: arginine depletion is rapid, but tumor regression and progression-free benefit take weeks to months to manifest because the mechanism is cytostatic and metabolic rather than directly cytotoxic. Trials therefore measured outcomes over 6- to 36-month windows.

=== Predecessor Trials That Set Up ATOMIC-Meso ===

Pegargiminase did not arrive at Phase 3 by surprise. A multi-year clinical-translational program built the case:

* '''ADAM trial (Szlosarek et al., ''JAMA Oncology'' 2017)''' — A randomized Phase 2 study of pegargiminase versus best supportive care in 68 patients with ASS1-deficient malignant pleural mesothelioma. Pegargiminase monotherapy doubled progression-free survival (3.2 vs 2.0 months; HR 0.56) and confirmed the biomarker-targeted strategy in vivo.<ref name="pmid:27584578"/>
* '''Phase 1 dose-escalation (Beddowes et al., ''JCO'' 2017)''' — Established the pegargiminase + pemetrexed + cisplatin combination at 36 mg/m² weekly with acceptable safety and signals of activity in ASS1-deficient thoracic cancers.<ref name="pmid:28388291"/>
* '''Expansion Phase 1 (Szlosarek et al., ''JTO Clinical and Research Reports'' 2020)''' — Expanded the combination study in ASS1-deficient mesothelioma and reported disease control in 94% of evaluable patients, with a median PFS in the 5- to 6-month range — directly motivating the Phase 3 design.<ref name="pmid:34589965"/>

By the time ATOMIC-Meso opened to enrollment, the mechanism, the dose, the schedule, the combination partner (pemetrexed/platinum), and the biomarker (ASS1 deficiency, enriched in nonepithelioid disease) were all pre-specified on the basis of earlier-phase evidence.

== Trial Design ==

ATOMIC-Meso (NCT02709512) was an international, multicenter, double-blind, randomized, placebo-controlled '''Phase 2-3 study'''. The trial was conducted at 43 centers across 5 countries, with enrollment running from August 1, 2017 through August 15, 2021 and final follow-up on August 15, 2022.<ref name="pmid:38358753"/>

=== Eligibility ===

* Histologically confirmed malignant pleural mesothelioma
* Nonepithelioid subtype: sarcomatoid or biphasic (epithelioid disease was excluded)
* Chemotherapy-naive — no prior systemic therapy for mesothelioma
* Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1
* Adequate organ function for platinum-doublet chemotherapy

Patients with prior pegargiminase exposure, active second malignancy, or contraindications to pemetrexed or platinum agents were excluded.

=== Randomization ===

249 patients were randomized 1:1 to one of two arms. Both patients and investigators were blinded to assignment. Mean age at randomization was 69.5 years (standard deviation 7.9), and 82.7% of enrolled patients were male.<ref name="pmid:38358753"/>

=== Treatment Arms ===

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse;"
|-
! style="background:#1a5276; color:white; padding:10px; text-align:left;" | Arm
! style="background:#1a5276; color:white; padding:10px; text-align:left;" | Regimen
|-
| style="padding:10px; font-weight:bold;" | Experimental
| style="padding:10px;" | Pegargiminase (Peg-arginine deiminase, ADI-PEG20) 36.8 mg/m² intramuscular (IM) weekly + pemetrexed 500 mg/m² intravenous (IV) on Day 1 of each 21-day cycle + cisplatin 75 mg/m² IV Day 1 (or carboplatin area-under-the-curve [AUC] 5 IV Day 1) for up to 6 cycles. Pegargiminase was continued until disease progression, unacceptable toxicity, or 24 months.
|-
| style="padding:10px; font-weight:bold;" | Control
| style="padding:10px;" | Placebo IM weekly + pemetrexed 500 mg/m² IV Day 1 + cisplatin 75 mg/m² IV Day 1 (or carboplatin AUC 5 IV Day 1) for up to 6 cycles. Placebo was continued until disease progression, unacceptable toxicity, or 24 months.
|}

=== Endpoints ===

* '''Primary endpoint:''' Overall survival (OS)
* '''Secondary endpoints:''' Progression-free survival (PFS), safety
* '''Response rate''' by blinded independent central review (BICR) was assessed in the Phase 2 portion only.

== Results ==

=== Overall Survival (Primary Endpoint) ===

ATOMIC-Meso met its primary endpoint of overall survival. Median OS was 9.3 months in the pegargiminase arm (95% CI 7.9–11.8) versus 7.7 months in the placebo arm (95% CI 6.1–9.5). The hazard ratio for death was 0.71 (95% CI 0.55–0.93; P = .02), corresponding to a 29% reduction in the risk of death.<ref name="pmid:38358753"/>

=== Progression-Free Survival (Secondary) ===

Median PFS was 6.2 months in the pegargiminase arm (95% CI 5.8–7.4) versus 5.6 months in the placebo arm (95% CI 4.1–5.9). The hazard ratio was 0.65 (95% CI 0.46–0.90; P = .02), representing a 35% reduction in the risk of progression or death.<ref name="pmid:38358753"/>

== Safety and Tolerability ==

Grade 3 or 4 adverse events occurred in 28.8% of patients in the pegargiminase arm (36 of 125) versus 16.9% in the placebo arm (21 of 124). Drug hypersensitivity reactions were reported in 3 patients (2.4%) in the pegargiminase arm and 0 patients in the placebo arm; skin reactions were reported in 2 patients (1.6%) in the pegargiminase arm and 0 in the placebo arm. Rates of poststudy treatments were comparable between arms — 45.6% with pegargiminase and 46.8% with placebo.<ref name="pmid:38358753"/>

Pegargiminase-specific safety considerations described in the published trial and supporting Phase 1 work include:

* '''Anti-drug antibodies (ADAs):''' Anti-pegargiminase antibodies are a known feature of bacterial-enzyme-derived therapeutics and have been reported across the pegargiminase development program.<ref name="pmid:28388291"/><ref name="pmid:34589965"/>
* '''Injection site reactions:''' Local reactions at the intramuscular injection site occurred in a minority of patients in earlier-phase studies and are typically Grade 1–2 and self-limited.<ref name="pmid:28388291"/>
* '''Hypersensitivity:''' Pre-treatment with antihistamines and corticosteroids has been used in pegargiminase studies to mitigate infusion-related reactions.

== Who Should Be Considered for Pegargiminase ==

ATOMIC-Meso enrolled and demonstrated benefit in a specific population:

* '''Histology:''' Sarcomatoid or biphasic (i.e., nonepithelioid) malignant pleural mesothelioma confirmed on biopsy
* '''Treatment status:''' Treatment-naive (first-line systemic therapy)
* '''Performance status:''' ECOG PS 0–1
* '''Organ function:''' Adequate for platinum-doublet chemotherapy

The trial did not enroll patients with epithelioid mesothelioma, peritoneal mesothelioma, or pretreated disease, and benefit in those populations cannot be assumed from the ATOMIC-Meso data. Phase 1/2 studies in epithelioid disease and in pretreated disease have shown some activity, but the Phase 3 evidence base is restricted to first-line nonepithelioid pleural mesothelioma.

'''ASS1 IHC testing''' is feasible and clinically informative. In the predecessor [[ADAM_Trial|ADAM trial]], ASS1-deficient status was the eligibility criterion, and biomarker-positive patients showed the largest benefit. ATOMIC-Meso enrolled by histology rather than by IHC because nonepithelioid disease enriches for ASS1 deficiency (~90%) at the population level. In clinical practice in 2026, decisions about whether to test ASS1 status — particularly for an epithelioid patient considering off-label access — are made case by case.

== Regulatory and Access Status (May 2026) ==

As of May 2026, pegargiminase + chemotherapy is '''not yet an FDA-approved indication for malignant pleural mesothelioma'''. The ATOMIC-Meso Phase 3 results were published in ''JAMA Oncology'' in April 2024, and the sponsor, Polaris Pharmaceuticals (Polaris Group), has been in regulatory discussions about an appropriate path to U.S. approval and parallel regulatory review in other jurisdictions.

Access is currently available through:

* '''Expanded access / compassionate use programs''' — typically requested by treating oncologists for individual patients on a case-by-case basis
* '''Investigator-initiated clinical trials''' — ongoing studies testing pegargiminase in combination with immunotherapy and in pretreated populations
* '''Off-label use at select academic centers''' — institutions where principal investigators have experience prescribing based on the published Phase 3 data

Patients and clinicians seeking access should contact a center actively running pegargiminase studies or consult Polaris Pharmaceuticals' medical-information channel.

== ATOMIC-Meso in the 2025–2026 Treatment Landscape ==

ATOMIC-Meso is one of several Phase 3 results reshaping mesothelioma therapy across the 2024–2026 reporting cycle:

* '''[[CheckMate_743_Trial|CheckMate 743]]''' — first-line nivolumab + ipilimumab versus chemotherapy. Approved by the FDA in October 2020 for unresectable pleural mesothelioma. The 5-year update published in ''Journal of Clinical Oncology'' in 2026 confirmed sustained survival benefit (~14% versus ~6% at 5 years, hazard ratio 0.74).
* '''ATOMIC-Meso''' — first-line pegargiminase + chemotherapy versus placebo + chemotherapy in nonepithelioid disease. Reported in ''JAMA Oncology'' April 2024.
* '''[[NIPU_Trial|NIPU Trial / UV1 vaccine]]''' — second-line UV1 telomerase peptide vaccine added to immunotherapy in pretreated mesothelioma.
* '''[[eVOLVE-Meso_Trial|eVOLVE-Meso]]''' — Phase 3 volrustomig (PD-1 × LAG-3 bispecific) in mesothelioma.
* '''[[MARS2_Trial|MARS2]]''' — extended pleurectomy/decortication (P/D) versus chemotherapy alone; reframed the role of cytoreductive surgery.

The collective picture for 2025–2026 is that nonepithelioid disease — historically the most poorly served subtype — now has both an immunotherapy option ([[CheckMate_743_Trial|CheckMate 743]]) and a metabolic-targeted option (ATOMIC-Meso). The next clinical-research question is how these mechanisms combine, sequence, or substitute for each other.

== Related Topics ==

* [[CheckMate_743_Trial|CheckMate 743 Trial]] — first-line nivolumab + ipilimumab immunotherapy
* [[NIPU_Trial|NIPU Trial / UV1 Vaccine]] — telomerase peptide vaccine in pretreated mesothelioma
* [[eVOLVE-Meso_Trial|eVOLVE-Meso Trial]] — volrustomig PD-1 × LAG-3 bispecific
* [[MARS2_Trial|MARS2 Trial]] — extended pleurectomy/decortication
* [[BAP1|BAP1 Gene Mutation]] — germline and somatic loss in mesothelioma
* [[ASS1|Argininosuccinate Synthetase 1 (ASS1)]] — metabolic biomarker
* [[Pleural_Mesothelioma|Pleural Mesothelioma]] — overview of disease subtypes
* [[Sarcomatoid_Mesothelioma|Sarcomatoid Mesothelioma]] — nonepithelioid subtype
* [[Biphasic_Mesothelioma|Biphasic Mesothelioma]] — mixed-histology subtype
* [[Pemetrexed|Pemetrexed Chemotherapy]] — backbone combination partner

== Glossary ==

* '''ADI-PEG20''' — Pegylated arginine deiminase 20,000 daltons; the development name for pegargiminase.
* '''ASS1''' — Argininosuccinate synthetase 1; a urea-cycle enzyme that catalyzes a key step in intracellular arginine synthesis.
* '''ECOG PS''' — Eastern Cooperative Oncology Group performance status; a 0–5 scale of functional status (0 = fully active; 4 = bedridden).
* '''IHC''' — Immunohistochemistry; a tissue-staining technique used here to assess ASS1 protein expression in tumor biopsies.
* '''IM''' — Intramuscular; the route of administration for pegargiminase (deep IM injection).
* '''Modified RECIST''' — Modified Response Evaluation Criteria in Solid Tumors; the standard radiologic response framework adapted specifically for the rind-pattern growth of pleural mesothelioma.
* '''Nonepithelioid mesothelioma''' — Sarcomatoid or biphasic subtypes; collectively ~35% of pleural mesothelioma cases; historically associated with worse outcomes than epithelioid disease.
* '''ORR''' — Objective response rate; the proportion of patients achieving a complete or partial response by RECIST.
* '''OS''' — Overall survival; time from randomization to death from any cause.
* '''PFS''' — Progression-free survival; time from randomization to first documented disease progression or death.
* '''Pegargiminase''' — Pegylated arginine deiminase; the active drug studied in ATOMIC-Meso.
* '''Pemetrexed''' — A folate antimetabolite chemotherapy agent used as the platinum-doublet partner in mesothelioma first-line therapy.

== References ==

<references/>

== External Links ==

* [https://clinicaltrials.gov/study/NCT02709512 ATOMIC-Meso (NCT02709512)] — ClinicalTrials.gov registry record
* [https://pubmed.ncbi.nlm.nih.gov/38358753/ Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial] — Szlosarek et al., ''JAMA Oncology'' 2024
* [https://pubmed.ncbi.nlm.nih.gov/27584578/ Arginine Deprivation With Pegylated Arginine Deiminase in ASS1-Deficient Mesothelioma] — Szlosarek et al., ''JAMA Oncology'' 2017 (ADAM trial)

[[Category:Clinical Trials]]
[[Category:Mesothelioma Treatment]]
[[Category:Phase 3 Trials]]
[[Category:Nonepithelioid Mesothelioma]]